Pfizer: Lymphoma, Large-Cell, Anaplastic trials

The registry lists 15 Lymphoma, Large-Cell, Anaplastic studies with Pfizer as lead sponsor. 0 are open to participants now and 5 have results posted.

Phase 1 8Phase 2 4Phase 3 1Phase 4 1No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell LymphomaTerminatedNCT03947255Phase 2Results posted
• ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell LymphomasCompletedNCT01777152Phase 3Results posted
• A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin StudyCompletedNCT00947856Phase 2Results posted
• A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell LymphomaCompletedNCT00866047Phase 2Results posted
• A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced CancerCompletedNCT00585195Phase 1Results posted
• A Safety Study of PF-08046044/SGN-35C in Adults With Advanced CancersTerminatedNCT06254495Phase 1
• A Safety Study of PF-08046045/SGN-35T in Adults With Advanced CancersTerminatedNCT06120504Phase 1
• Crizotinib Continuation Clinical StudyActive, not recruitingNCT05160922Phase 4
• A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell NeoplasmsCompletedNCT01309789Phase 1
• A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001No longer availableNCT01196208
• Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)CompletedNCT01026415Phase 1
• Cardiac Safety Study of Brentuximab Vedotin (SGN-35)CompletedNCT01026233Phase 1
• A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive MalignanciesTerminatedNCT00649584Phase 1
• Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic MalignanciesCompletedNCT00430846Phase 1
• Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell LymphomaCompletedNCT00079755Phase 2